The introduction of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication suggests to deliver impressive improvements in fat reduction compared to current therapies. Early research studies hav